IFNA17 and systemic lupus erythematosus: Patients with at least one neutralizing Ab against an IFNα subtype displayed significantly lower disease activity (as measured by the British Isles Lupus Assessment Group [BILAG] global score [GS]) compared with patients without anti-IFN-Abs in circulation or patients with non-neutralizing anti-IFN-Abs (Figure 2A).